---
schema_version: "secwatch.filing_event.v1"
accession: "0001816736-25-000006"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:08:09.284310+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q2 net loss $55.2M; on track for bitopertin NDA in October 2025

## Summary
- Cash of $650.0M as of June 30, 2025; expected to fund operations into 2028.
- NDA submission for bitopertin in EPP under accelerated approval planned for October 2025 after positive pre-NDA meeting.
- Phase 2 data from DISC-0974 in MF anemia and multiple-dose data from Phase 1b in NDD-CKD anemia expected Q4 2025.
- Initiated Phase 2 study of DISC-3405 in polycythemia vera; initial data anticipated in 2026.
- Appointed Nadim Ahmed (Cullinan Therapeutics CEO) to Board of Directors in July 2025.

## SEC filing metadata
- accession: 0001816736-25-000006
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/0001816736-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/iron-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816736-25-000006
- JSON: https://secwatch.observer/filing/0001816736-25-000006.json
- Plain text: https://secwatch.observer/filing/0001816736-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.